ClinicalTrials.gg
RecruitingNCT04686305DL03Updated Apr 13, 2026

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

A Phase 1 interventional study of T-DXd and Durvalumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer, sponsored by AstraZeneca. Recruiting at 91 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2021; still recruiting 5 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
304
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing trastuzumab deruxtecan in Carcinoma, Non-Small-Cell Lung — 5 open to participants now, 9 under way, 2 of them phase 3. trastuzumab deruxtecan · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
4th of 12
304 · median 167
Started
2021
with 2 others
Phase 1
2 of 12
1 open now
Registered
5th of 12
by date
Lead sponsor
4 of 12
AstraZeneca

Among the 12 studies testing trastuzumab deruxtecan in Carcinoma, Non-Small-Cell Lung, this one is the 4th largest by planned enrollment, is one of 3 that started in 2021, is one of 2 in phase 1, and was the 5th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

5 of the 12 studies testing trastuzumab deruxtecan in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About trastuzumab deruxtecan

trastuzumab deruxtecan: first FDA approval 2019 (ENHERTU), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing trastuzumab deruxtecan in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

DESTINY-Lung03 will investigate the safety and tolerability of trastuzumab deruxtecan in combination with Immunotherapy Agents with and without chemotherapy in patients with HER2 over-expressing non-small cell lung cancer. The efficacy will be also analyzed as a secondary endpoint.

Read the detailed description

Part 1 is a dose escalation study by design, allowing the assessment of safety, tolerability, and recommended dose levels of the combination of T-DXd and durvalumab plus cisplatin, carboplatin, or pemetrexed. No more patients will be enrolled in this part of the study. Part 2, expansions in the treatment-naïve setting on any recommended dose level, will not be initiated.

The evaluation of T-DXd combination treatment with immunotherapy continues in Part 3, Part 4, and Part 5. In Part 3, T-DXd is assessed in combination with volrustomig, with carboplatin (Arm 3B) or without carboplatin (Arm 3A). Part 4 examines T-DXd with rilvegostomig, either with carboplatin (Arm 4B) or without carboplatin (Arm 4A). In Part 5, T-DXd is evaluated with volrustomig, given with or without a priming dose followed by a fixed dose in Arm 5A. There is also an optional Arm 5B at the Sponsor's discretion. These parts focus on further dose optimization for first-line HER2-overexpressing NSCLC.

For Part 3, patients will be randomized to Arms 3A and 3B, beginning with the cohorts receiving the volrustomig starting dose (SD). A total of 6 DLT-evaluable patients will be enrolled to the SD cohorts in each arm. If the combination of T-DXd with volrustomig at the starting dose is deemed safe, a dose escalation (E1) cohort will be opened for 6 DLT-evaluable patients. Once all open dose confirmation cohorts have 6 DLT-evaluable patients, the SRC will convene to select the volrustomig RP2D to be used in the dose-expansion (DE) cohorts of each arm (n=34). Part 3 is now permanently closed to recruitment; no further patients will be enrolled.

In Part 4, once a total of 6 DLT-evaluable patients/arm have been enrolled into Arm 4A and Arm 4B safety-run in (SR) cohorts and deemed safe, an additional 34 patients per arm will be enrolled in Arms 4A and 4B in dose expansion cohorts.

Part 5 involves additional dosing regimens of T-DXd in combination with volrustomig. The objective of Part 5 is to evaluate the safety and efficacy of priming and flat dosing regimens in 2 different cohorts of up to 30 patients per arm.

The target population of interest (for Part 3, 4 and 5) are patients with advanced or metastatic non-small cell lung cancer measurable disease by RECIST 1.1 criteria, HER2 overexpression, ECOG PS of 0 to 1, patients who are treatment naïve for recurrent, unresectable or metastatic disease. Patients with tumors that harbor a known genomic alteration or driver for which approved therapies are available are excluded.

03

Conditions studied

  • Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Keywords

  • HER2+
  • HER2 expression
  • DS-8201a
  • T-DXd
  • Trastuzumab Deruxtecan
  • Volrustomig (MEDI5752)
  • Antibody - drug conjugate
  • bispecific antibody
  • Volrustomig
  • Rilvegostomig
  • Carboplatin
  • First line
  • Locally advanced and unresectable non-squamous NSCLC
  • Metastatic non-squamous NSCLC
  • Non-small cell lung cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • documented unresectable locally advanced/ non-squamous NSCLC
  • Part 1: Progression after 1 or 2 for recurrent or metastatic setting.
  • Part 3, Part 4 and Part 5: Patients must have tumors that do not harbor known genomic alterations or actionable driver kinases, for which approved therapies are available are allowed.
  • Part 3, Part 4 and Part 5: Patient must be treatment-naïve for advanced or metastatic NSCLC. Patients who have received prior adjuvant, or chemotherapy, or definitive chemoradiation for advanced disease are eligible, provided that progression has occurred > 6 months from end of last therapy
  • HER2overexpression status as determined by central review of tumor tissue
  • WHO / performance status of 0 or 1
  • Measurable target disease assessed by the investigator using 1.1
  • Has protocol defined adequate organ and bone marrow function
  • Part 3, Part 4 and Part 5: Minimum body weight of 35 kg.

Exclusion criteria

Exclusion criteria:

  • mutation if previously known
  • Has a history of (non-infectious) ILD/pneumonitis that required , has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening
  • Lung-specific intercurrent illnesses including, but not limited to, any underlying pulmonary disorder and prior pneumonectomy
  • Active primary immunodeficiency known infection, or active chronic and resolved (positive hepatitis B virus surface antigen [HBsAg+ve] or hepatitis B virus core antibody (anti-HBc +ve) regardless of HBV DNA level)) or infection. Patients positive for HCV antibody are eligible only if polymerase chain reaction is negative for HCV RNA. Patients should be tested for HIV prior to treatment assignment if required by local regulations or IRB/EC
  • Active infection including tuberculosis and uncontrolled infection requiring IV antibiotics, antivirals, or antifungals
  • Spinal cord compression or clinically active central nervous system , defined as untreated and symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms
  • Medical history of myocardial infarction within 6 months before treatment assignment, symptomatic CHF ( Class II to IV), clinically important cardiac arrhythmias, or a recent (\< 6 months) cardiovascular event including stroke
  • For Part 3, Part 4 and Part 5: Cardiomyopathy of any etiology, symptomatic CHF (as defined by New York Heart Association Class > II), unstable angina pectoris, history of MI within the past 12 months, or cardiac arrhythmia are to be excluded. Patients with troponin levels above at screening (as defined by the manufacturer), and without any myocardial related symptoms, should have a cardiologic consultation before treatment assignment to rule out acute cardiopulmonary events.
  • Ascites or pericardial effusion that requires drainage, peritoneal shunt, Pleuroperitoneal shunt or CART (Concentrated Ascites Reinfusion Therapy)
  • For Part 3, Part 4 and Part 5: Active non-infectious skin disease (including any grade rash, urticarial, dermatitis, ulceration, or psoriasis) requiring systemic treatment, active or prior documented or inflammatory disorders requiring chronic treatment with steroids or other treatment.
  • Unresolved toxicities not yet resolved to Grade ≤ 1 or baseline from previous anticancer therapy OR prior discontinuation of any planned study therapy due to toxicity.
  • must not have any medical to platinum-based chemotherapy.
  • Part 3, Part 4 and Part 5 patients must not have had prior exposure to , anti-PD-L1, anti-CTLA-4, anti-TIGIT or any other experimental immunotherapy in any setting.
  • For Part 3, Part 4 and Part 5: History of substance abuse or any other medical or psychological conditions that may, in the opinion of the Investigator, interfere with the subject's participation in the clinical study or evaluation of the clinical study results
  • For Part 3, Part 4 and Part 5: History of thromboembolic events within 3 months before the first dose of IP (limited to pulmonary embolism, deep vein thrombosis, or cerebral venous sinus thrombosis).
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
304 participants (estimated)

Study arms

  • Experimental
    Arm 1A: T-DXd, Durvalumab and Cisplatin

    T-DXd, Durvalumab and Cisplatin

    Drug: T-DXd · Biological: Durvalumab · Drug: Cisplatin

  • Experimental
    Arm 1B: T-DXd, Durvalumab and Carboplatin

    T-DXd, Durvalumab and Carboplatin

    Drug: T-DXd · Biological: Durvalumab · Drug: Carboplatin

  • Experimental
    Arm 1C: T-DXd, Durvalumab and Pemetrexed

    T-DXd, Durvalumab and Pemetrexed (Arm not initiated)

    Drug: T-DXd · Biological: Durvalumab · Drug: Pemetrexed

  • Experimental
    Arm 1D: T-DXd

    T-DXd

    Drug: T-DXd

  • Experimental
    Arm 3A: T-DXd and Volrustomig

    Drug: T-DXd and Volrustomig T-DXd: administered as an IV infusion Other Name: DS-8201a, Trastuzumab deruxtecan Biological/Vaccine: Volrustomig Volrustomig: administered as an IV infusion Other Name: Volrustomig

    Drug: T-DXd · Drug: Volrustomig

  • Experimental
    Arm 3B: T-DXd, Volrustomig and Carboplatin

    Drug: T-DXd, Volrustomig and Carboplatin T-DXd: administered as an IV infusion Other Name: DS-8201a, Trastuzumab deruxtecan Biological/Vaccine: Volrustomig Volrustomig: administered as an IV infusion Other Name: Volrustomig Drug: Carboplatin Carboplatin: administered as an IV infusion

    Drug: T-DXd · Drug: Carboplatin · Drug: Volrustomig

  • Experimental
    Arm 4A: T-DXd and Rilvegostomig

    T-DXd and Rilvegostomig Drug: T-DXd, Rilvegostomig T-DXd: administered as an IV infusion Other Name: DS-8201a, Trastuzumab deruxtecan Biological/Vaccine: Rilvegostomig Rilvegostomig: administered as an IV infusion Other Name: Rilvegostomig, AZD2936

    Drug: T-DXd · Drug: Rilvegostomig

  • Experimental
    Arm 4B T-DXd and Rilvegostomig with Carboplatin

    Drug: T-DXd, Rilvegostomig and Carboplatin T-DXd: administered as an IV infusion Other Name: DS-8201a, Trastuzumab deruxtecan Biological/Vaccine: Rilvegostomig Rilvegostomig: administered as an IV infusion Other Name: Rilvegostomig, AZD2936 Drug: Carboplatin Carboplatin: administered as an IV infusion

    Drug: T-DXd · Drug: Carboplatin · Drug: Rilvegostomig

  • Experimental
    Arm 5A: T-DXd and Volrustomig

    Drug: T-DXd and volrustomig T-DXd: administered as an IV infusion Other Name: DS-8201a, trastuzumab deruxtecan Biological/Vaccine: Volrustomig Volrustomig: administered as an IV infusion (priming dose in first cycle, fixed dose in subsequent cycles) Other Name: volrustomig

    Drug: T-DXd · Drug: Volrustomig

  • Experimental
    Arm 5B: T-DXd and Volrustomig

    Drug: T-DXd and volrustomig T-DXd: administered as an IV infusion Other Name: DS-8201a, trastuzumab deruxtecan Biological/Vaccine: Volrustomig Volrustomig: administered as an IV infusion (fixed dose from first cycle onward) Other Name: volrustomig

    Drug: T-DXd · Drug: Volrustomig

Interventions

  • DrugT-DXd

    T-DXd: administered as an IV infusion

    Also known as: DS-8201a, Trastuzumab deruxtecan

  • BiologicalDurvalumab

    Durvalumab: administered as an IV infusion

    Also known as: MEDI4736

  • Cisplatin: administered as an IV infusion

  • Carboplatin: administered as an IV infusion

  • Pemetrexed: administered as an IV infusion (drug not used)

  • Volrustomig: administered as an IV infusion

    Also known as: Other Name: MEDI5752

  • Rilvegostomig: administered as an IV infusion

    Also known as: Other Name: AZD2936

06

What researchers measure

Primary outcomes

  1. Frequency of AEs and SAEs

    Occurrence of AEs and SAEs graded according to NCI CTCAE v5.0

    Time frame: Safety and tolerability (and to determine RP2D) will be assessed for approximately 20 months from informed consent

Secondary outcomes

  1. Confirmed Objective Response Rate (ORR)

    Confirmed ORR per RECIST 1.1 is the percentage of patients with Complete Response or Partial Response that is subsequently confirmed, based on investigator assessment

    Time frame: An average of approximately 12 months

  2. Duration of Response (DoR)

    DOR is defined as the time from the date of first documented response until the date of documented progression or death, based on RECIST 1.1 assessment

    Time frame: An average of approximately 20 months

  3. Disease Control Rate (DCR)

    DCR is the percentage of patients who have a best overall response of complete response (CR) or partial response (PR) or stable disease (SD), based on RECIST 1.1 assessment. DCR is assessed at 6 and 12 weeks

    Time frame: An average of approximately 12 months

  4. Progression-free survival (PFS)

    PFS is the time from first dose of study treatment until the date of objective disease progression or death, based on RECIST 1.1 assessment

    Time frame: An average of approximately 20 months

  5. Overall survival (OS)

    OS is the time form the date of first dose of study treatment until death due to any cause

    Time frame: An average of approximately 20 months

  6. Pharmacokinetics (PK) assessed by the serum concentration of T-DXd, total anti-HER2 antibody, and MAAA-1181 in all arms

    Individual patient data and descriptive statistics will be provided for serum concentration data at each time point for T-DXd, total anti-HER2 antibody and MAAA-1181a

    Time frame: An average of approximately 20 months

  7. Pharmacokinetics (PK) assessed by the serum concentration of durvalumab in study arms including T-DXd in combination with durvalumab

    Individual patient data and descriptive statistics will be provided for serum concentration data at each time point for durvalumab, including T-DXd in combination with durvalumab

    Time frame: An average of approximately 20 months

  8. Pharmacokinetics (PK) assessed by the serum concentration of volrustomig in study arms including T-DXd in combination with volrustomig

    Individual patient data and descriptive statistics will be provided for serum concentration data at each time point for volrustomig, including T-DXd in combination with volrustomig

    Time frame: An average of approximately 20 months

  9. Pharmacokinetics (PK) assessed by the serum concentration of rilvegostomig in study arms including T-DXd in combination with rilvegostomig

    Individual patient data and descriptive statistics will be provided for serum concentration data at each time point for rilvegostomig, including T- DXd in combination with rilvegostomig

    Time frame: An average of approximately 20 months

  10. The immunogenicity of T-DXd, durvalumab, volrustomig and rilvegostomig assessed by the presence of ADAs for T-DXd, durvalumab, volrustomig, or rilvegostomig

    Individual participant data and descriptive statistics will be provided for data at each time point for each dose level for T-DXd, durvalumab or volrustomig, or rilvegostomig

    Time frame: An average of approximately 20 months

07

Study locations

47 of 91 sites recruiting
  • Research Site
    Duarte, California 91010, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Newport Beach, California 92663, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Orange, California 92868, United States
    Recruiting
  • Research Site
    Santa Rosa, California 95403, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Westwood, Kansas 66205, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Baltimore, Maryland 21287, United States
    Recruiting
  • Research Site
    Detroit, Michigan 48201, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Buffalo, New York 14263, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    New York, New York 10029, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    The Bronx, New York 10461, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Houston, Texas 77030, United States
    Recruiting
  • Research Site
    Fairfax, Virginia 22031, United States
    Recruiting
  • Research Site
    Tacoma, Washington 98405, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Adelaide, 5000, Australia
    Terminated

    Not enrolling at this site — choose another above.

  • Research Site
    Heidelberg, 3084, Australia
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Nedlands, 6009, Australia
    Recruiting
  • Research Site
    Edegem, 2650, Belgium
    Completed

    Not enrolling at this site — choose another above.

  • Research Site
    Barretos, 14784-400, Brazil
    Recruiting
  • Research Site
    Porto Alegre, 90035-903, Brazil
    Recruiting
  • Research Site
    São Paulo, 05652-900, Brazil
    Recruiting
  • Research Site
    Winnipeg, Manitoba R3E 0V9, Canada
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    London, Ontario N6A 5W9, Canada
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Montreal, Quebec H3T 1E2, Canada
    Recruiting
  • Research Site
    Changchun, 130000, China
    Not yet recruiting
  • Research Site
    Chengdu, 610041, China
    Not yet recruiting
  • Research Site
    Fuzhou, 350011, China
    Not yet recruiting
  • Research Site
    Shandong, China
    Not yet recruiting
  • Research Site
    Shanghai, 200433, China
    Recruiting
  • Research Site
    Zhengzhou, 450000, China
    Not yet recruiting
  • Research Site
    Bordeaux, 33075, France
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Dijon, 21079, France
    Recruiting
  • Research Site
    Pierre-Bénite, 69495, France
    Recruiting
  • Research Site
    Saint-Herblain, 44800, France
    Recruiting
  • Research Site
    Villejuif, 94805, France
    Recruiting
  • Research Site
    Kfar Saba, 4428164, Israel
    Recruiting
  • Research Site
    Tel Litwinsky, 52620, Israel
    Recruiting
  • Research Site
    Milan, 20133, Italy
    Completed

    Not enrolling at this site — choose another above.

  • Research Site
    Milan, 20162, Italy
    Recruiting
  • Research Site
    Monza, 20052, Italy
    Recruiting
  • Research Site
    Naples, 80131, Italy
    Recruiting
  • Research Site
    Padova, 35128, Italy
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    George Town, 10450, Malaysia
    Recruiting
  • Research Site
    Kuala Lumpur, 59100, Malaysia
    Recruiting
  • Research Site
    Kuala Selangor, 62250, Malaysia
    Recruiting
  • Research Site
    Kuching, 93586, Malaysia
    Recruiting
  • Research Site
    Amsterdam, 1066 CX, Netherlands
    Completed

    Not enrolling at this site — choose another above.

  • Research Site
    Bacolod, 6100, Philippines
    Recruiting
  • Research Site
    Cebu City, 6000, Philippines
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    City of Taguig, 1634, Philippines
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Davao City, PH-8000, Philippines
    Terminated

    Not enrolling at this site — choose another above.

  • Research Site
    Manila, 1000, Philippines
    Terminated

    Not enrolling at this site — choose another above.

  • Research Site
    Manila, 1015, Philippines
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Quezon City, 1100, Philippines
    Recruiting
  • Research Site
    Quezon City, 1112, Philippines
    Recruiting
  • Research Site
    San Juan City, 1500, Philippines
    Terminated

    Not enrolling at this site — choose another above.

  • Research Site
    Gdansk, 80-214, Poland
    Recruiting
  • Research Site
    Krakow, 30-727, Poland
    Suspended

    Not enrolling at this site — choose another above.

  • Research Site
    Olsztyn, 10-357, Poland
    Recruiting
  • Research Site
    Tomaszów Mazowiecki, 97-200, Poland
    Terminated

    Not enrolling at this site — choose another above.

  • Research Site
    Warsaw, 02-781, Poland
    Recruiting
  • Research Site
    Singapore, 119228, Singapore
    Completed

    Not enrolling at this site — choose another above.

  • Research Site
    Singapore, 168583, Singapore
    Completed

    Not enrolling at this site — choose another above.

  • Research Site
    Singapore, 308433, Singapore
    Completed

    Not enrolling at this site — choose another above.

  • Research Site
    Cheongju-si, 28644, South Korea
    Recruiting
  • Research Site
    Goyang-si, 10408, South Korea
    Recruiting
  • Research Site
    Jinju, 52727, South Korea
    Recruiting
  • Research Site
    Seoul, 03722, South Korea
    Recruiting
  • Research Site
    Seoul, 05505, South Korea
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Seoul, 06351, South Korea
    Recruiting
  • Research Site
    Badalona, 08013, Spain
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Madrid, 28041, Spain
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Seville, 41013, Spain
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Valencia, 46010, Spain
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Kaohsiung City, 833, Taiwan
    Recruiting
  • Research Site
    Taichung, 402, Taiwan
    Recruiting
  • Research Site
    Taichung, 40705, Taiwan
    Recruiting
  • Research Site
    Tainan, 70403, Taiwan
    Recruiting
  • Research Site
    Taipei, 100, Taiwan
    Recruiting
  • Research Site
    Taipei, 11217, Taiwan
    Recruiting
  • Research Site
    Taipei, 235, Taiwan
    Recruiting
  • Research Site
    Taoyuan, 333, Taiwan
    Recruiting
  • Research Site
    Bangkok, 10300, Thailand
    Recruiting
  • Research Site
    Bangkok, 10330, Thailand
    Completed

    Not enrolling at this site — choose another above.

  • Research Site
    Hat Yai, 90110, Thailand
    Completed

    Not enrolling at this site — choose another above.

  • Research Site
    Khon Kaen, 40002, Thailand
    Completed

    Not enrolling at this site — choose another above.

  • Research Site
    Muang, 22000, Thailand
    Not yet recruiting
  • Research Site
    Muang, 50200, Thailand
    Recruiting
  • Research Site
    Ankara, 06800, Turkey (Türkiye)
    Recruiting
  • Research Site
    Ankara, 6200, Turkey (Türkiye)
    Recruiting
  • Research Site
    Bornova-Izmir, 35100, Turkey (Türkiye)
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Istanbul, 31755, Turkey (Türkiye)
    Recruiting
08

References and documents

Publications

  • Planchard D, Kim HR, Suksombooncharoen T, Li R, Cortinovis D, Han JY, Samol J, Runglodvatana Y, Lee KY, Chang GC, Lee CH, Kowalski D, Saw SPL, Huang Y, Ruiter G, Ahn MJ, Yang TY, Yang CT, Sookprasert A, Nakajima EC, Alfon J, McEwen R, Chang YT, Yang JC. Trastuzumab Deruxtecan in Patients With HER2-Overexpressing NSCLC: Results From Part 1 of the Open-Label, Multicenter, Phase 1b DESTINY-Lung03 Trial. J Thorac Oncol. 2026 May;21(5):103541. doi: 10.1016/j.jtho.2025.12.080. Epub 2025 Dec 23. PubMed 41448488 ↗

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2021 (actual). Primary completion is estimated for Jun 2027, 75 months after the start.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's planned 75 months is above that.

Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2020
First posted
Dec 28, 2020
StartActual
Mar 9, 2021
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04686305
Lead sponsor
AstraZeneca
Collaborators
Daiichi Sankyo
Responsible party
Sponsor
First posted
Dec 28, 2020
Start date
Mar 9, 2021
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Apr 13, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479
AstraZeneca Lung Cancer Study Locator Service
Contact
az-lcsl@careboxhealth.com
1-884-432-3892

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab deruxtecan

Start the discussion